First Wave BioPharma announces publication of research on celiac disease

First Wave BioPharma announced research generated from two previously completed Phase 2 clinical trials of latiglutenase has been published in the special issue “Recent Advances in Gluten-Free Diet and Celiac Disease” in the peer-reviewed scientific journal, Nutrients. Latiglutenase, an oral biotherapeutic composed of two gluten-specific recombinant proteases, is a potentially first-in-class, targeted, oral biotherapeutic for celiac disease. The featured paper is entitled “Dynamics of Serologic Change to Gluten in Celiac Disease Patients”. The manuscript benefits from one of the largest databases of CeD clinical results from several Phase 2 clinical trials for latiglutenase and addresses two issues: the return to seropositivity for CeD patients who resume a gluten containing diet for diagnostic purposes and the correlation between two different tTG-IgA assays at their defined upper limit of normal thresholds. “Our focus on developing latiglutenase is bolstered by this groundbreaking CeD research, just one component of the scientific, clinical, and regulatory expertise in gastroenterological drug development that Jack Syage and his team, formerly from ImmunogenX, bring to First Wave,” stated James Sapirstein, Chairman and CEO of First Wave. “The potential for latiglutenase to transform treatment is backed by solid data from these Phase 2 trials, which have shown latiglutenase to be safe, well-tolerated, and effective at breaking down the gluten proteins that lead to intestinal damage and the symptoms of celiac disease.”